ScholarIQanswers from OpenAlex & ORCID
Jonathan S. Berek
ResearcherPublications, citations & collaboration network
Jonathan S. Berek is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jonathan S. Berek have?
ScholarIQindexed works
Jonathan S. Berek has 475 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jonathan S. Berek have?
ScholarIQcitation count
Jonathan S. Berek has 32,219 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jonathan S. Berek?
ScholarIQh-index
Jonathan S. Berek has an h-index of 85 in OpenAlex.
What is the i10-index of Jonathan S. Berek?
ScholarIQi10-index
Jonathan S. Berek has an i10-index of 256 in OpenAlex.
What is the ORCID of Jonathan S. Berek?
ScholarIQorcid
The ORCID for Jonathan S. Berek is on the source record.
What is the OpenAlex record for Jonathan S. Berek?
ScholarIQopenalex
The OpenAlex for Jonathan S. Berek is on the source record.
What are the most-cited papers on Jonathan S. Berek?
ScholarIQmost cited works
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
William A. Peters, P.Y. Liu, Rolland J. Barrett, Richard J. Stock, Bradley J. Monk, Jonathan S. Berek, Luís Souhami, Perry W. Grigsby, William Gordon, David S. Alberts
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan, Jermaine Coward, Robert C. Bast, Andy Berchuck, Jonathan S. Berek, James D. Brenton, George Coukos, Christopher Crum, Ronny Drapkin, Dariush Etemadmoghadam, Michael Friedländer, Hani Gabra, Stan B. Kaye, Christopher J. Lord, Ernst Lengyel, Douglas A. Levine, Iain A. McNeish, Usha Menon, Gordon B. Mills, Kenneth P. Nephew, Amit M. Oza, Anil K. Sood, Euan A. Stronach, Henning Walczak, David D.L. Bowtell, Frances R. Balkwill
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, B.J. Rimel, Daniela Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M. del Campo, Ursula A. Matulonis, Susanne Malander, Diane Provencher, Sven Mahner, Philippe Follana, Justin S. Waters, Jonathan S. Berek, Kathrine Woie, Amit M. Oza, Ulrich Canzler, Marta Gil-Martín, Anne Lesoin, Bradley J. Monk, Bente Lund, Lucy Gilbert, Robert M. Wenham, Benedict B. Benigno, Sujata Arora, Sebastien Hazard, Mansoor Raza Mirza